Expert Opinion on Investigational Drugs [ISSN 1354-3784]; [e-ISSN 1744-7658] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers on drugs in preclinical and early-stage clinical development, providing expert opinion on the scope for future development. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.

Expert Opinion on Investigational Drugs address the needs of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.

The Editors welcome:

    Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies.
    Drug Evaluations reviewing the clinical and pharmacological data on a particular drug.
    Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials.

Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:

Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;

Article Highlights – an executive summary of the author’s most critical points.

Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.

Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Opinion on Investigational Drugs, part of the Expert Collection brand.

EDITOR-IN-CHIEF 
Giuseppe Tonini - University Campus Bio-Medico, Italy

EDITORIAL ADVISORY BOARD
Naim Alkhouri - Texas Liver Institute, San Antonio, Texas, USA 
Karl-Eric Andersson - Wake Forest University, NC, USA 
Wilbert Aronow - New York Medical College, NY , USA 
Guglielmo Borgia - University of Naples Federico II, Italy 
Martin Braddock - AstraZeneca, Loughborough, England, UK 
Maria Luisa Brandi - University of Florence, Italy 
Linda Cardozo - King's College London, England, UK 
Thomas Ciulla - Indiana University School of Medicine, Indianapolis, IN, USA 
Jerry Colca - Kalamazoo Metabolic Research, MI, USA 
Mellar Davis - Taussig Cancer Institute, OH, USA 
William Denny - University of Auckland, New Zealand 
Nafsika Georgopapadakou - MethylGene, Montreal, Canada 
Lars Grundemar - Ferring Pharmaceuticals, Denmark 
Percy Ivy – National Cancer Institute, MD, USA 
Michael Koutsilieris - University of Athens, Greece 
Renu Kowluru - Kresge Eye Institute, MI, USA 
Dimitri Mikhalidis - University College London, England, UK 
Nouri Naemati - University of Southern California, CA, USA 
Athanasios Papatsoris - University of Athens, Greece 
Athanasios Papavassiliou - University of Athens, Greece 
Godefridus J. Peters - Amsterdam UMC, The Netherlands 
Marwan N Sabbagh - Banner Sun Health Research Institute, USA 
Tomi Sawyer - Merck Research Laboratories, MA, USA 
Nicola Silvestris – Cancer Institute, 'Giovanni Paolo II’, Italy 
Noel J Snell - Royal Brompton Hospital, London, England, UK 
Guru Sonpavde - Dana Farber Cancer Institute, MA, USA 
Christoph Stein - Charité Campus Benjamin Franklin, Berlin, Germany 
Eleftherios Tsiridis - Imperial College, London, England, UK 
László Vecsei - University of Szeged, Hungary 
Stephan von Haehling - University of Göttingen, Germany 
Robert Williams - Cancer Research UK 
Martyn Wood - UCB Pharma, Belgium